Developer docs
API playgroundTry for free, no card

Search company profiles

A-Alpha Bio

Full company profile

uuid000089t

Namestring
A-Alpha Bio
Legal namestring
A-Alpha Bio, Inc.
Websiteurl
aalphabio.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

A-Alpha Bio is a Seattle-based private biotechnology company founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. The company combines synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions, operating an integrated platform of two core products: AlphaSeq, an experimental platform that uses yeast surface display libraries to quantitatively measure millions of protein-protein binding affinities simultaneously, and AlphaBind, a machine learning system trained on 750+ million affinity measurements that predicts binding strength from protein sequence. The company has measured over one billion protein-protein interactions to date and has expanded the platform with AlphaSeq 3D (small-molecule screening for molecular glue discovery) and AlphaPan (an in-house 100B+ diversity phage display antibody library).

The company serves pharmaceutical companies, biotechnology firms, academic research institutions, and government/defense agencies. Strategic enterprise partnerships include Bristol Myers Squibb and Amgen for molecular glue discovery, Gilead Sciences for broadly neutralizing HIV antibody engineering, and a Department of Defense-funded collaboration with Lawrence Livermore National Laboratory for biothreat antibody discovery totaling approximately $16.9M in grant funding across 2023-2024. Additional customers include Bayer, Memorial Sloan Kettering Cancer Center, Broad Institute, and Voyager Therapeutics, with recent channel expansion through integration into Amazon Web Services' Amazon Bio Discovery platform as a CRO partner.

A-Alpha Bio generates revenue primarily through platform-as-a-service contracts with pharmaceutical partners for antibody discovery, optimization, and protein-protein interaction data generation, supplemented by collaborative drug discovery programs that include milestone-based funding and potential downstream royalties. The company employs 101-250 staff and has raised approximately $60M+ across equity rounds (a $20M Series A in 2021 led by Madrona and a $22.4M round in 2023 led by Perceptive Advisors) and non-dilutive government grants. Revenue is not publicly disclosed.

Short descriptiontext

A-Alpha Bio is a Seattle-based biotechnology company that combines synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions for pharmaceutical companies, research institutions, and government agencies developing biologics, molecular glues, and antibody therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
protein interaction measurement, antibody discovery services, machine learning drug discovery, synthetic biology platforms, biologics engineering services
Industry3 codes
PRIMARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Drug Discovery Platforms
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Platform-as-a-Service for Partners
TypeProfessional Services
Description

A-Alpha Bio offers its AlphaSeq platform as a service to pharmaceutical partners and research institutions to obtain high-resolution protein binding data at library-on-library scale. Revenue is generated through service contracts with pharmaceutical companies for antibody discovery, optimization, and data generation. Partnerships include major pharma companies (BMS, Amgen, Gilead) and research institutions.

aalphabio.com
2Collaborative Drug Discovery Programs
TypeLicensing Royalties
Description

The company conducts collaborative therapeutic development programs with pharmaceutical partners, such as the partnership with Gilead to engineer a broadly neutralizing HIV treatment, and partnerships with Amgen and Bristol Myers Squibb for molecular glue discovery. These partnerships likely involve milestone-based funding and potential downstream royalties.

aalphabio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

A-Alpha Bio provides proprietary protein-protein interaction measurement and prediction platforms, combining synthetic biology (AlphaSeq) with machine learning (AlphaBind) to enable pharmaceutical and biotech partners to discover and optimize antibodies, molecular glues, and other biologics. The company delivers its platforms as a service, generating on-demand high-throughput binding affinity data and ML-guided design support for partners including Bristol Myers Squibb, Amgen, Gilead Sciences, the U.S. Department of Defense, and academic institutions.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

A-Alpha Bio offers an integrated platform of two core products: AlphaSeq (experimental platform for multiplexed protein-protein interaction measurement) and AlphaBind (computational platform for ML-based binding prediction), working together in a continuous improvement cycle. The AlphaSeq + AlphaBind platform is supplemented by AlphaPan (100B+ antibody phage library) and AlphaSeq 3D (small molecule screening extension). The company operates both as a platform provider for pharmaceutical partners (Bristol Myers Squibb, Amgen, Gilead, Google) and as a CRO service provider generating on-demand protein interaction data.

Product and service4 records
1AlphaSeq
CategoryDrug Discovery Platforms / Experimental Protein Interaction Measurement
Description

Proprietary experimental platform for quantitative, multiplexed measurement of protein-protein binding affinities using synthetic biology and yeast surface display libraries. Measures physiologically relevant interaction strengths spanning picomolar to micromolar affinities and has generated over one billion protein-protein interactions across antibodies, cell surface receptors, intracellular proteins, bacterial/viral antigens, and peptides. Delivered as a service to pharmaceutical and biotech partners for antibody discovery, optimization, and on-demand data generation.

2AlphaBind
CategoryDrug Discovery Platforms / Computational Binding Prediction
Description

Machine learning platform trained on over 750 million protein-protein affinity measurements that predicts binding strength from protein sequence. Predicts expression, stability, solubility, and other developability properties to enrich designs. Supports rapid design-validate iteration cycles of approximately six weeks with AlphaSeq, enabling partners to fuel and refine predictive ML models for antibody and biologics discovery.

3AlphaSeq 3D
CategoryDrug Discovery Platforms / Small Molecule Screening
Description

Extended version of the AlphaSeq experimental platform that directly screens small molecule libraries against networks of effectors and targets to identify molecular glue compounds that induce proximity between proteins. Designed to amplify hit rates for molecular glue discovery campaigns.

4AlphaPan
CategoryDrug Discovery Platforms / Antibody Display Libraries
Description

In-house phage display library featuring a diversity of over 100 billion antibodies, used to discover hundreds of sequence- and epitope-diverse antibody hits against targets of interest. Serves as a starting input for downstream AlphaSeq and AlphaBind workflows.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-07
Description

A-Alpha Bio is listed as a CRO partner (coming soon) in Amazon Web Services' Amazon Bio Discovery platform. The platform enables researchers to computationally design antibody candidates and submit them directly to CRO partners including A-Alpha Bio for wet-lab synthesis and testing, with results automatically flowing back into the application to improve subsequent design cycles.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-02
Description

Partnership to accelerate AI-enabled antibody discovery by integrating A-Alpha Bio's AlphaSeq experimental validation platform directly into Tamarind Bio's computational biology tools. The partnership enables researchers using AI design tools like RFdiffusion and ProteinMPNN to submit predicted antibody sequences for quantitative binding affinity measurements, creating a seamless closed-loop workflow from in silico design to experimental validation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-21
Description

Collaboration with Lawrence Livermore National Laboratory supported by Department of Defense funding ($14.5 million in 2024, $2.4 million in 2023) to generate large-scale antibody-antigen binding data for drug discovery against biological threats. The effort focuses on training machine learning models for antibody design targeting multiple pathogen families, including biothreats, and aims to develop rapid response capabilities against emerging biothreats, building on success with coronavirus and other pathogen families.

4Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership for molecular glue discovery. The collaboration aims to identify and validate novel weak interactions to inform molecular glue discovery campaigns, unlocking previously undruggable targets and broadening the impact of induced proximity therapeutics.

aalphabio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership for molecular glue discovery, leveraging A-Alpha Bio's platform to measure otherwise undetectable interactions between effector and target proteins at unprecedented scale and sensitivity.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Gilead to engineer a broadly neutralizing HIV treatment using cross-reactive binders targeting species homologs and highly mutable viruses. Also involved in other antibody engineering applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding institution partnership. A-Alpha Bio was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. Ongoing research partnership.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner logo displayed on company website, indicating partnership for global health initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding institution partnership. A-Alpha Bio was founded at UW's Institute for Protein Design.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Antibody discovery platform company combining high-throughput wet-lab screening with AI/ML. Direct competitor in the antibody discovery and protein-protein interaction measurement space, also partnering with major pharma companies.

TypeDirect peer
Description

Generative biology company using machine learning to design novel protein therapeutics. Most direct competitor in the AI-enabled protein engineering and biologics discovery space, with significantly larger funding.

TypeDirect peer
Description

Discovery and optimization platform for antibody-based therapeutics, with a yeast-based antibody display technology similar in approach to A-Alpha Bio's AlphaSeq. Comparable in operating model (platform-as-a-service to pharma partners).

TypeDirect peer
Description

AI-powered generative antibody design company combining in-silico design with high-throughput wet-lab validation. Publicly-listed direct peer with a similar integrated approach to antibody discovery and optimization.

TypeDirect peer
Description

AI/ML-driven antibody design platform using a wet-lab + computational closed loop similar to A-Alpha Bio's AlphaSeq + AlphaBind approach. Direct competitor in ML-enabled antibody engineering.

6Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned drug discovery company applying AI (from DeepMind/AlphaFold) to pharmaceutical R&D. Broader scope than A-Alpha Bio but overlaps in computational protein design and binding prediction; substantially better capitalized.

TypeDirect peer
Description

AI protein engineering company offering generative models for protein design. Direct competitor in the AI-protein design space, with a software-and-services go-to-market model.

TypeBroad incumbent
Description

TechBio company combining high-throughput biology with AI/ML for drug discovery. Broader scope than A-Alpha Bio but overlapping in wet-lab + ML platform approach; public company with major pharma partnerships (including Roche, Bayer).

9Antiverse
TypeEmerging player
Description

UK-based AI antibody design startup using generative AI and computational biology. Emerging competitor in AI-driven antibody discovery with a narrower scope and earlier stage than A-Alpha Bio.

TypeOthers
Description

Biopharmaceutical company using biology and chemistry to discover and develop therapeutics, with established partnerships with pharma on biologics. Thematically adjacent through induced-proximity and biologics discovery, though not a direct platform competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

A-Alpha Bio

Drug Discovery Platformsaalphabio.com

A-Alpha Bio is a Seattle-based biotechnology company that combines synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions for pharmaceutical companies, research institutions, and government agencies developing biologics, molecular glues, and antibody therapeutics.

What A-Alpha Bio does

A-Alpha Bio is a Seattle-based private biotechnology company founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. The company combines synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions, operating an integrated platform of two core products: AlphaSeq, an experimental platform that uses yeast surface display libraries to quantitatively measure millions of protein-protein binding affinities simultaneously, and AlphaBind, a machine learning system trained on 750+ million affinity measurements that predicts binding strength from protein sequence. The company has measured over one billion protein-protein interactions to date and has expanded the platform with AlphaSeq 3D (small-molecule screening for molecular glue discovery) and AlphaPan (an in-house 100B+ diversity phage display antibody library).

The company serves pharmaceutical companies, biotechnology firms, academic research institutions, and government/defense agencies. Strategic enterprise partnerships include Bristol Myers Squibb and Amgen for molecular glue discovery, Gilead Sciences for broadly neutralizing HIV antibody engineering, and a Department of Defense-funded collaboration with Lawrence Livermore National Laboratory for biothreat antibody discovery totaling approximately $16.9M in grant funding across 2023-2024. Additional customers include Bayer, Memorial Sloan Kettering Cancer Center, Broad Institute, and Voyager Therapeutics, with recent channel expansion through integration into Amazon Web Services' Amazon Bio Discovery platform as a CRO partner.

A-Alpha Bio generates revenue primarily through platform-as-a-service contracts with pharmaceutical partners for antibody discovery, optimization, and protein-protein interaction data generation, supplemented by collaborative drug discovery programs that include milestone-based funding and potential downstream royalties. The company employs 101-250 staff and has raised approximately $60M+ across equity rounds (a $20M Series A in 2021 led by Madrona and a $22.4M round in 2023 led by Perceptive Advisors) and non-dilutive government grants. Revenue is not publicly disclosed.

A-Alpha Bio firmographics

Firmographics
Name
A-Alpha Bio
Legal name
A-Alpha Bio, Inc.
Website
https://aalphabio.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
A-Alpha Bio is a Seattle-based biotechnology company that combines synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions for pharmaceutical companies, research institutions, and government agencies developing biologics, molecular glues, and antibody therapeutics.
Ownership category
akta.pro rank

A-Alpha Bio industry classification

Industry
Product category
Drug Discovery Platforms
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Protein interaction measurement
  • Antibody discovery services
  • Machine learning drug discovery
  • Synthetic biology platforms
  • Biologics engineering services

Where A-Alpha Bio is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

A-Alpha Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Platform-as-a-Service for Partners: A-Alpha Bio offers its AlphaSeq platform as a service to pharmaceutical partners and research institutions to obtain high-resolution protein binding data at library-on-library scale. Revenue is generated through service contracts with pharmaceutical companies for antibody discovery, optimization, and data generation. Partnerships include major pharma companies (BMS, Amgen, Gilead) and research institutions.
  2. Collaborative Drug Discovery Programs: The company conducts collaborative therapeutic development programs with pharmaceutical partners, such as the partnership with Gilead to engineer a broadly neutralizing HIV treatment, and partnerships with Amgen and Bristol Myers Squibb for molecular glue discovery. These partnerships likely involve milestone-based funding and potential downstream royalties.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

A-Alpha Bio product offering

Product offering

Core offering

A-Alpha Bio provides proprietary protein-protein interaction measurement and prediction platforms, combining synthetic biology (AlphaSeq) with machine learning (AlphaBind) to enable pharmaceutical and biotech partners to discover and optimize antibodies, molecular glues, and other biologics. The company delivers its platforms as a service, generating on-demand high-throughput binding affinity data and ML-guided design support for partners including Bristol Myers Squibb, Amgen, Gilead Sciences, the U.S. Department of Defense, and academic institutions.

Product overview

A-Alpha Bio offers an integrated platform of two core products: AlphaSeq (experimental platform for multiplexed protein-protein interaction measurement) and AlphaBind (computational platform for ML-based binding prediction), working together in a continuous improvement cycle. The AlphaSeq + AlphaBind platform is supplemented by AlphaPan (100B+ antibody phage library) and AlphaSeq 3D (small molecule screening extension). The company operates both as a platform provider for pharmaceutical partners (Bristol Myers Squibb, Amgen, Gilead, Google) and as a CRO service provider generating on-demand protein interaction data.

Differentiator

Problem solved

Functional benefit

Products and services

  • AlphaSeq Proprietary experimental platform for quantitative, multiplexed measurement of protein-protein binding affinities using synthetic biology and yeast surface display libraries. Measures physiologically relevant interaction strengths spanning picomolar to micromolar affinities and has generated over one billion protein-protein interactions across antibodies, cell surface receptors, intracellular proteins, bacterial/viral antigens, and peptides. Delivered as a service to pharmaceutical and biotech partners for antibody discovery, optimization, and on-demand data generation.
  • AlphaBind Machine learning platform trained on over 750 million protein-protein affinity measurements that predicts binding strength from protein sequence. Predicts expression, stability, solubility, and other developability properties to enrich designs. Supports rapid design-validate iteration cycles of approximately six weeks with AlphaSeq, enabling partners to fuel and refine predictive ML models for antibody and biologics discovery.
  • AlphaSeq 3D Extended version of the AlphaSeq experimental platform that directly screens small molecule libraries against networks of effectors and targets to identify molecular glue compounds that induce proximity between proteins. Designed to amplify hit rates for molecular glue discovery campaigns.
  • AlphaPan In-house phage display library featuring a diversity of over 100 billion antibodies, used to discover hundreds of sequence- and epitope-diverse antibody hits against targets of interest. Serves as a starting input for downstream AlphaSeq and AlphaBind workflows.

Companies that use A-Alpha Bio

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

A-Alpha Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature4 records

A-Alpha Bio partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Amazon Web Services (Amazon Bio Discovery)coreChannel Partner/ Reseller/ Distributor · 7 May 2026A-Alpha Bio is listed as a CRO partner (coming soon) in Amazon Web Services' Amazon Bio Discovery platform. The platform enables researchers to computationally design antibody candidates and submit them directly to CRO partners including A-Alpha Bio for wet-lab synthesis and testing, with results automatically flowing back into the application to improve subsequent design cycles.
  • Tamarind BiocoreTechnology or Integration · 2 April 2026Partnership to accelerate AI-enabled antibody discovery by integrating A-Alpha Bio's AlphaSeq experimental validation platform directly into Tamarind Bio's computational biology tools. The partnership enables researchers using AI design tools like RFdiffusion and ProteinMPNN to submit predicted antibody sequences for quantitative binding affinity measurements, creating a seamless closed-loop workflow from in silico design to experimental validation.
  • Lawrence Livermore National Laboratory (LLNL)coreStrategic or Co-development Partner · 21 May 2024Collaboration with Lawrence Livermore National Laboratory supported by Department of Defense funding ($14.5 million in 2024, $2.4 million in 2023) to generate large-scale antibody-antigen binding data for drug discovery against biological threats. The effort focuses on training machine learning models for antibody design targeting multiple pathogen families, including biothreats, and aims to develop rapid response capabilities against emerging biothreats, building on success with coronavirus and other pathogen families.
  • Bristol Myers SquibbcoreStrategic or Co-development PartnerStrategic partnership for molecular glue discovery. The collaboration aims to identify and validate novel weak interactions to inform molecular glue discovery campaigns, unlocking previously undruggable targets and broadening the impact of induced proximity therapeutics.
  • AmgencoreStrategic or Co-development PartnerStrategic partnership for molecular glue discovery, leveraging A-Alpha Bio's platform to measure otherwise undetectable interactions between effector and target proteins at unprecedented scale and sensitivity.
  • Gilead SciencescoreStrategic or Co-development PartnerPartnership with Gilead to engineer a broadly neutralizing HIV treatment using cross-reactive binders targeting species homologs and highly mutable viruses. Also involved in other antibody engineering applications.
  • University of WashingtoncoreStrategic or Co-development PartnerFounding institution partnership. A-Alpha Bio was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. Ongoing research partnership.
  • Bill & Melinda Gates FoundationminorStrategic or Co-development PartnerPartner logo displayed on company website, indicating partnership for global health initiatives.
  • Institute for Protein Design (IPD)coreStrategic or Co-development PartnerFounding institution partnership. A-Alpha Bio was founded at UW's Institute for Protein Design.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

A-Alpha Bio competitors and assessment

Company assessment

Direct peers

  • AbCellera Biologics: Antibody discovery platform company combining high-throughput wet-lab screening with AI/ML. Direct competitor in the antibody discovery and protein-protein interaction measurement space, also partnering with major pharma companies.
  • Generate Biomedicines: Generative biology company using machine learning to design novel protein therapeutics. Most direct competitor in the AI-enabled protein engineering and biologics discovery space, with significantly larger funding.
  • Adimab: Discovery and optimization platform for antibody-based therapeutics, with a yeast-based antibody display technology similar in approach to A-Alpha Bio's AlphaSeq. Comparable in operating model (platform-as-a-service to pharma partners).
  • Absci: AI-powered generative antibody design company combining in-silico design with high-throughput wet-lab validation. Publicly-listed direct peer with a similar integrated approach to antibody discovery and optimization.
  • BigHat Biosciences: AI/ML-driven antibody design platform using a wet-lab + computational closed loop similar to A-Alpha Bio's AlphaSeq + AlphaBind approach. Direct competitor in ML-enabled antibody engineering.
  • Cradle Bio: AI protein engineering company offering generative models for protein design. Direct competitor in the AI-protein design space, with a software-and-services go-to-market model.

Broad incumbents

  • Isomorphic Labs: Alphabet-owned drug discovery company applying AI (from DeepMind/AlphaFold) to pharmaceutical R&D. Broader scope than A-Alpha Bio but overlaps in computational protein design and binding prediction; substantially better capitalized.
  • Recursion Pharmaceuticals: TechBio company combining high-throughput biology with AI/ML for drug discovery. Broader scope than A-Alpha Bio but overlapping in wet-lab + ML platform approach; public company with major pharma partnerships (including Roche, Bayer).

Emerging players

  • Antiverse: UK-based AI antibody design startup using generative AI and computational biology. Emerging competitor in AI-driven antibody discovery with a narrower scope and earlier stage than A-Alpha Bio.

Others

  • Denali Therapeutics: Biopharmaceutical company using biology and chemistry to discover and develop therapeutics, with established partnerships with pharma on biologics. Thematically adjacent through induced-proximity and biologics discovery, though not a direct platform competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

A-Alpha Bio social profiles

Digital presence

A-Alpha Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

A-Alpha Bio leadership team

Management profile

Number of profiles

Profiles10 records

A-Alpha Bio funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

A-Alpha Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about A-Alpha Bio

What does A-Alpha Bio do?

A-Alpha Bio provides proprietary protein-protein interaction measurement and prediction platforms, combining synthetic biology (AlphaSeq) with machine learning (AlphaBind) to enable pharmaceutical and biotech partners to discover and optimize antibodies, molecular glues, and other biologics. The company delivers its platforms as a service, generating on-demand high-throughput binding affinity data and ML-guided design support for partners including Bristol Myers Squibb, Amgen, Gilead Sciences, the U.S. Department of Defense, and academic institutions.

Is A-Alpha Bio a public or private company?

A-Alpha Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was A-Alpha Bio founded?

A-Alpha Bio was founded in 2017. It employs 11 to 50 people.

Where is A-Alpha Bio based?

A-Alpha Bio is headquartered in Seattle, United States, in the North America region.

How does A-Alpha Bio make money?

Two revenue lines are on record. Platform-as-a-Service for Partners are the primary driver. The others are collaborative Drug Discovery Programs.

Who are A-Alpha Bio's main competitors?

Direct peers on record are AbCellera Biologics, Generate Biomedicines, Adimab, Absci, BigHat Biosciences and Cradle Bio. Broad incumbents are Isomorphic Labs and Recursion Pharmaceuticals. Antiverse is listed as an emerging player. Denali Therapeutics is listed as an others.

Does A-Alpha Bio have an API?

No public API is recorded for A-Alpha Bio.

What industry is A-Alpha Bio in?

A-Alpha Bio's product category is Drug Discovery Platforms. Its primary akta.pro industry code is HLAAAIAH, Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireA-Alpha Bio Announces Industry-First Data Consortium to Solve AI Protein Engineering's Experimental Data Bottleneck. Founding members include GSK, Boltz, Cradle, and Dyno Therapeutics.A-Alpha Bio announced the founding members of its Atlas Consortium, an industry-first collaborative model for generating and sharing standardized experimental antibody-antigen data to advance AI-enabled drug discovery, launching with GSK, Boltz, Cradle, and Dyno Therapeutics as founding members. The consortium enables members to design and pool new experimental datasets quarterly through A-Alpha Bio's AlphaSeq platform, providing each member approximately 28 million affinity measurements per year at launch, scaling to 100 million annually as membership grows. The initiative addresses a critical bottleneck in AI protein engineering where high-quality experimental data has been closely guarded, with members quoting that better data and models will accelerate therapeutic development and reduce costs.Endpoints NewsA-Alpha Bio starts AI antibody data consortium with GSK, BoltzA-Alpha Bio, a spinout from David Baker's lab led by CEO David Younger, has launched an AI antibody data consortium with pharmaceutical company GSK and biotech firm Boltz as founding participants. The consortium aims to address biopharma's need for high-quality antibody binding data to train AI systems, positioning A-Alpha Bio to sell this data as a business model.GlobeNewswireA-Alpha Bio Launches Atlas to Address the Data Bottleneck in AI-Enabled Protein DesignA-Alpha Bio, a Seattle-based synthetic biology and machine learning biotechnology company, launched Atlas, a new web platform that provides licensable ML-ready protein interaction data and custom data generation services to address a critical bottleneck in AI-enabled drug discovery. The platform is powered by the company's AlphaSeq technology, which has generated 450 million affinity measurements and over 7,000 lab-validated antibody-antigen pseudo-structures. Atlas offers data licensing for existing datasets and custom data generation through dedicated data blocks or the Atlas Consortium, which aggregates data across subscribers for model training and benchmarking purposes.Amazon Web ServicesClosing the Loop with Amazon Bio Discovery’s Integrated Lab PartnersAmazon Web Services announced the expansion of Amazon Bio Discovery, an AI-powered antibody drug discovery platform, by integrating it with a network of contract research organization (CRO) partners including Twist Bioscience, Ginkgo Bioworks, and A-Alpha Bio (coming soon). The platform enables researchers to computationally design antibody candidates and submit them directly to CRO partners for wet-lab synthesis and testing, with results automatically flowing back into the application to improve subsequent design cycles. The CRO partners provide services spanning DNA synthesis, protein expression, biophysical characterization, and developability assays, with the goal of making high-quality laboratory services accessible to academic labs, early-stage biotechs, and smaller research teams.The Manila TimesTamarind Bio Partners with A-Alpha Bio to Streamline Experimental Validation for AI-Enabled Antibody DiscoveryTamarind Bio and A-Alpha Bio announced a partnership to accelerate AI-enabled antibody engineering by integrating A-Alpha Bio's AlphaSeq experimental validation platform directly into Tamarind Bio's computational biology platform. The integration allows researchers using AI design tools like RFdiffusion and ProteinMPNN to submit predicted antibody sequences for high-throughput experimental validation, providing quantitative binding affinity data and a scalable feedback loop between computational predictions and real-world measurements. This addresses a key bottleneck in AI-driven antibody discovery where confirming binding affinity and specificity remains slow and resource-intensive despite AI models' ability to rapidly generate candidate sequences.GlobeNewswireTamarind Bio Partners with A-Alpha Bio to Streamline Experimental Validation for AI-Enabled Antibody DiscoveryTamarind Bio and A-Alpha Bio have announced a partnership to accelerate AI-enabled antibody discovery by integrating A-Alpha Bio's AlphaSeq experimental validation platform directly into Tamarind Bio's computational biology tools. The partnership enables researchers using AI design tools like RFdiffusion and ProteinMPNN to submit predicted antibody sequences for quantitative binding affinity measurements, creating a seamless closed-loop workflow from in silico design to experimental validation. Both companies view this integration as addressing a critical bottleneck in the antibody discovery pipeline where confirming binding affinity and specificity has traditionally been slow and resource-intensive.GlobeNewswireA-Alpha Bio Awarded Additional $14.5M from the Department of Defense to Accelerate Antibody Discovery and Optimization for Likely BiothreatsA-Alpha Bio received $14.5M in additional funding from the Department of Defense's GUIDE program to expand its partnership with Lawrence Livermore National Laboratory. The funds will generate large-scale antibody-antigen binding datasets and train predictive models for undisclosed pathogen families. The collaboration has already measured nearly 10 million binding affinities across three pathogen families.YahooA-Alpha Bio Nets $22.4M For Groundbreaking Protein Interaction PredictionsA-Alpha Bio raised $22.4 million in a Series A extension led by Perceptive Xontogeny Venture Fund. The startup uses AI and yeast to predict protein interactions, partnering with Bristol-Myers Squibb, Lawrence Livermore National Laboratory, and Gilead Sciences. The funding aims to accelerate drug, enzyme, and biosensor development.GeekWireA-Alpha Bio, a biotech startup that measures and predicts protein interactions, raises $22.4MSeattle biotech startup A-Alpha Bio raised $22.4 million in a Series A extension round led by Perceptive Xontogeny Ventures, with participation from Madrona Venture Group and new investor Breakout Ventures. The company develops machine learning tools that analyze protein-protein interactions using a database of nearly 500 million measurements, and has partnerships with pharmaceutical companies including Bristol Myers Squibb and Gilead Sciences. The funding will support growth and runway toward milestone achievement before the next fundraising round.GoogleMethods for identifying protein coding sequences using dna barcodesA patent disclosure describes methods for identifying protein-coding regions in polynucleotide libraries using DNA barcodes. It uses a silent first barcode within the coding region and a random second barcode upstream, enabling identification via short-read sequencing. The methods aim to resolve mutational variants that differ by single base pairs.